Journal
JOURNAL OF HEPATOLOGY
Volume 73, Issue 2, Pages 423-440Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2020.04.011
Keywords
Non-alcoholic fatty liver disease; NAFLD; Non-alcoholic steatohepatitis; NASH; ALD; Fibrosis; Cirrhosis; Primary liver cancer
Categories
Funding
- Spanish Ministry of Science
- Instituto de Salud Carlos III [PI17/00012, SAF2016-78711, SAF2017-87919-R]
- ERAB [EA 18/14]
- AMMF [2018/117, UCM-25-2019]
- COST Action [CA17112]
- German Research Foundation [SFB/TRR57/P04, SFB 1382-403224013/A02, DFG NE 2128/2-1]
- Swiss National Science Foundation [SNF 320030_189252/1]
- Swiss Foundation Against Liver Cancer
- Swiss Foundation for Liver Diseases
- Novartis Foundation for medical-biological research
- Funds FEDER from the European Union
- AGAUR [2017-SGR-517]
- CERCA Program from the Generalitat de Catalunya
- Ramon y Cajal [RYC-2014-15242, RYC-2015-17438]
- [EXO-HEP-CM S2017/BMD-3727]
- [NanoLiver-CM Y2018/NMT-4949]
Ask authors/readers for more resources
Animal models are crucial for improving our understanding of human pathogenesis, enabling researchers to identify therapeutic targets and test novel drugs. In the current review, we provide a comprehensive summary of the most widely used experimental models of chronic liver disease, starting from early stages of fatty liver disease (non-alcoholic and alcoholic) to steatohepatitis, advanced cirrhosis and end-stage primary liver cancer. We focus on aspects such as reproducibility and practicality, discussing the advantages and weaknesses of available models for researchers who are planning to perform animal studies in the near future. Additionally, we summarise current and prospective models based on human tissue bioengineering. (c) 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available